Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
about
Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC)Comparison of the diagnostic performance of (18)F-fluorothymidine versus (18)F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis.[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patientsTotal Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.Single-scan dual-tracer FLT+FDG PET tumor characterization.New strategy for monitoring targeted therapy: molecular imaging.Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy.Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.Methodology for quantitative rapid multi-tracer PET tumor characterizationsPET/CT in therapy evaluation of patients with lung cancer.FLT PET-CT in evaluation of treatment response.The role of PET/CT as a prognosticator and outcome predictor in lung cancer.TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.The engagement of FDG PET/CT image quality and harmonized quantification: from competitive to complementary.Optimisation and harmonisation: two sides of the same coin?
P2860
Q30926992-2F5B9C61-2259-4E19-A610-891EAEDF1BB8Q34607468-49E40131-16D8-4B27-B871-2F090D1BCD07Q35088202-CA3B789C-19CA-407A-B7C4-418B812D3F23Q36006242-68D8AB23-CF01-434A-B8EB-57201DDF64DFQ36558260-84693133-14C7-4611-9D1D-37C803B072E9Q37225316-33F5424E-50EE-4491-971B-753847A67CFAQ37273224-AEF206CE-286D-4D0F-AC1C-E541CE897E6CQ37324886-ECDCE93E-EBDE-4729-82F3-E68C38750FE9Q37342653-5CA90761-A1BB-4BF4-B318-96ACE5945240Q38202189-68C201AC-9CDD-4271-9E63-9949189B70F3Q38206772-235EB1A5-7758-4DE8-BEE1-D1C126BB58DDQ38715401-2FA94159-87C8-466F-A3C9-BB734881C943Q38853578-507265AB-7325-487B-BFCB-1E873AB06AC7Q41888643-A4237549-2584-4F43-B6D3-A576D799F972Q44453305-FB0A796D-FBFD-48CA-A180-8B1736D1429CQ53109430-6B4393B1-8CFB-41A4-A19D-9620FEF03803
P2860
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Predictive value of early and ...... cancer treated with erlotinib.
@en
Predictive value of early and ...... cancer treated with erlotinib.
@nl
type
label
Predictive value of early and ...... cancer treated with erlotinib.
@en
Predictive value of early and ...... cancer treated with erlotinib.
@nl
prefLabel
Predictive value of early and ...... cancer treated with erlotinib.
@en
Predictive value of early and ...... cancer treated with erlotinib.
@nl
P2093
P2860
P50
P1476
Predictive value of early and ...... cancer treated with erlotinib.
@en
P2093
Arne Holstein
Carsten Kobe
Deniz Kahraman
Jürgen Wolf
Lucia Nogova
Markus Dietlein
Roland T Ullrich
Thomas Zander
P2860
P2888
P304
P356
10.1007/S00259-012-2118-8
P577
2012-04-14T00:00:00Z